S146 Evaluation of Engraftment and Diversity Following Open-Label Administration of CP101, an Investigational Oral Microbiome Therapeutic for the Prevention of Recurrent C. difficile Infection, in the PRISM-EXT Trial. (October 2022) - Kelly, Colleen